Vertex Pharmaceuticals VRTX had recently announced sustained Virologic Response (SVR) of 75% in the 12-week response guided therapy of Telaprevir arms. The pharma company also intends to begin filing a rolling NDA this summer for Telaprevir.
According to a report released by Piper Jaffray, the company is conducting a phase II combination study of Telaprevir amd polymerase inhibitor VX-222. The research firm has reiterated its overweight rating for the stock and has set its price target at $52. The price target is based on NPV of projected corporate cash flow through 2020 discounted back at 17%. The company may face regulatory and commercial risks.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorAnalyst RatingsBiotechnologyHealth CarePiper JaffrayTelecommunication ServicesWireless Telecommunication Services
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in